Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. It provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. The company markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.

TELA Bio, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

MALVERN, PA., DEC. 12, 2025 (GLOBE NEWSWIRE) -- TELA BIO, INC. ("TELA BIO") (NASDAQ: TELA), A COMMERCIAL-STAGE MEDICAL TECHNOLOGY COMPANY FOCUSED ON PROVIDING INNOVATIVE SOFT-TISSUE RECONSTRUCTION SOLUTIONS, TODAY ANNOUNCED THAT THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS OF TELA BIO APPROVED INDUCEMENT GRANTS OF RESTRICTED STOCK UNITS COVERING 3,600 SHARES OF ITS COMMON STOCK TO THREE NEWLY-HIRED EMPLOYEES, WITH A GRANT DATE OF DECEMBER 9, 2025 (THE "GRANT DATE"). THE RESTRICTED STOCK UNITS WERE GRANTED PURSUANT TO THE NASDAQ RULE 5635(C)(4) INDUCEMENT GRANT EXCEPTION AS A COMPONENT OF EACH INDIVIDUAL'S EMPLOYMENT COMPENSATION AND WERE GRANTED AS AN INDUCEMENT MATERIAL TO HIS OR HER ACCEPTANCE OF EMPLOYMENT WITH TELA BIO.

TELA BIO ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

MALVERN, PA., NOV. 19, 2025 (GLOBE NEWSWIRE) -- TELA BIO, INC. (NASDAQ: TELA), A COMMERCIAL-STAGE MEDICAL TECHNOLOGY COMPANY FOCUSED ON PROVIDING INNOVATIVE SOFT-TISSUE RECONSTRUCTION SOLUTIONS, TODAY ANNOUNCED THAT THE COMPANY WILL PARTICIPATE IN PIPER SANDLER'S 37TH ANNUAL HEALTHCARE CONFERENCE.

TELA BIO TO PARTICIPATE IN THE PIPER SANDLER 37TH ANNUAL HEALTHCARE CONFERENCE

MALVERN, PA., NOV. 17, 2025 (GLOBE NEWSWIRE) -- TELA BIO, INC. ("TELA BIO") (NASDAQ: TELA), A COMMERCIAL-STAGE MEDICAL TECHNOLOGY COMPANY FOCUSED ON PROVIDING INNOVATIVE SOFT-TISSUE RECONSTRUCTION SOLUTIONS, TODAY ANNOUNCED THAT THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS OF TELA BIO APPROVED INDUCEMENT GRANTS OF (I) RESTRICTED STOCK UNITS COVERING 30,200 SHARES OF ITS COMMON STOCK TO SEVENTEEN NEWLY-HIRED EMPLOYEES AND (II) AN OPTION TO PURCHASE 25,000 SHARES OF ITS COMMON STOCK TO ONE EMPLOYEE, WITH A GRANT DATE OF NOVEMBER 10, 2025 (THE "GRANT DATE"). THE EQUITY AWARDS WERE GRANTED PURSUANT TO THE NASDAQ RULE 5635(C)(4) INDUCEMENT GRANT EXCEPTION AS A COMPONENT OF EACH INDIVIDUAL'S EMPLOYMENT COMPENSATION AND WERE GRANTED AS AN INDUCEMENT MATERIAL TO HIS OR HER ACCEPTANCE OF EMPLOYMENT WITH TELA BIO.

MALVERN, PA., NOV. 13, 2025 (GLOBE NEWSWIRE) -- TELA BIO, INC. ("TELA"), A COMMERCIAL-STAGE MEDICAL TECHNOLOGY COMPANY FOCUSED ON PROVIDING INNOVATIVE SOFT-TISSUE RECONSTRUCTION SOLUTIONS, TODAY ANNOUNCED THE PRICING OF AN UNDERWRITTEN REGISTERED DIRECT OFFERING OF 4,189,000 SHARES OF ITS COMMON STOCK AT A PRICE OF $1.11 PER SHARE AND, IN LIEU OF COMMON STOCK TO INVESTORS WHO SO CHOOSE, PRE-FUNDED WARRANTS TO PURCHASE 7,523,000 SHARES OF COMMON STOCK AT AN OFFERING PRICE OF $1.1099 PER PRE-FUNDED WARRANT, WHICH REPRESENTS THE PER SHARE OFFERING PRICE FOR THE SHARES OF COMMON STOCK LESS THE $0.0001 PER SHARE EXERCISE PRICE. THE GROSS PROCEEDS TO TELA FROM THE OFFERING, BEFORE DEDUCTING UNDERWRITING DISCOUNTS AND ESTIMATED OFFERING EXPENSES, ARE EXPECTED TO BE APPROXIMATELY $13.0 MILLION, ASSUMING NO EXERCISE OF THE PRE-FUNDED WARRANTS. THE OFFERING IS EXPECTED TO CLOSE ON OR ABOUT NOVEMBER 17, 2025, SUBJECT TO THE SATISFACTION OF CUSTOMARY CLOSING CONDITIONS.

TELA BIO ANNOUNCES PRICING OF $13.0 MILLION UNDERWRITTEN REGISTERED DIRECT OFFERING OF COMMON STOCK AND PRE-FUNDED WARRANTS

MALVERN, PA., NOV. 13, 2025 (GLOBE NEWSWIRE) -- TELA BIO, INC. ("TELA BIO"), A COMMERCIAL-STAGE MEDICAL TECHNOLOGY COMPANY FOCUSED ON PROVIDING INNOVATIVE SOFT-TISSUE RECONSTRUCTION SOLUTIONS, TODAY REPORTED FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2025.

TELA BIO REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND REFINANCING AND UPSIZING OF CREDIT FACILITY

MALVERN, PA., OCT. 09, 2025 (GLOBE NEWSWIRE) -- TELA BIO, INC. (TELA BIO) (NASDAQ: TELA), A COMMERCIAL-STAGE MEDICAL TECHNOLOGY COMPANY FOCUSED ON PROVIDING INNOVATIVE SOFT-TISSUE RECONSTRUCTION SOLUTIONS, TODAY ANNOUNCED THE APPOINTMENT OF BETTY JO ROCCHIO, DNP, RN, CRNA, CENP, EBP-C, TO ITS BOARD OF DIRECTORS, AND THE DEPARTURE OF LISA COLLERAN, WHO HAS STEPPED DOWN FOLLOWING FIVE YEARS OF SERVICE ON THE BOARD.

TELA BIO ANNOUNCES ADDITION OF BETTY JO ROCCHIO TO BOARD OF DIRECTORS AND THE DEPARTURE OF DIRECTOR LISA COLLERAN

MALVERN, PA., AUG. 11, 2025 (GLOBE NEWSWIRE) -- TELA BIO, INC. ("TELA BIO"), A COMMERCIAL-STAGE MEDICAL TECHNOLOGY COMPANY FOCUSED ON PROVIDING INNOVATIVE SOFT-TISSUE RECONSTRUCTION SOLUTIONS, TODAY REPORTED FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2025.

TELA BIO REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS

MALVERN, PA., AUG. 08, 2025 (GLOBE NEWSWIRE) -- TELA BIO, INC. ("TELA BIO") (NASDAQ: TELA), A COMMERCIAL-STAGE MEDICAL TECHNOLOGY COMPANY FOCUSED ON PROVIDING INNOVATIVE SOFT-TISSUE RECONSTRUCTION SOLUTIONS, TODAY ANNOUNCED THAT THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS OF TELA BIO APPROVED INDUCEMENT GRANTS OF RESTRICTED STOCK UNITS COVERING 10,200 SHARES OF ITS COMMON STOCK TO FOURTEEN NEWLY-HIRED EMPLOYEES, WITH A GRANT DATE OF AUGUST 5, 2025 (THE "GRANT DATE"). THE RESTRICTED STOCK UNITS WERE GRANTED PURSUANT TO THE NASDAQ RULE 5635(C)(4) INDUCEMENT GRANT EXCEPTION AS A COMPONENT OF EACH INDIVIDUAL'S EMPLOYMENT COMPENSATION AND WERE GRANTED AS AN INDUCEMENT MATERIAL TO HIS OR HER ACCEPTANCE OF EMPLOYMENT WITH TELA BIO.

MALVERN, PA., JULY 23, 2025 (GLOBE NEWSWIRE) -- TELA BIO, INC. (NASDAQ: TELA), A COMMERCIAL-STAGE MEDICAL TECHNOLOGY COMPANY FOCUSED ON PROVIDING INNOVATIVE SOFT-TISSUE RECONSTRUCTION SOLUTIONS, TODAY ANNOUNCED THAT THE COMPANY WILL PARTICIPATE IN THE CANACCORD GENUITY 45TH ANNUAL GROWTH CONFERENCE.

TELA BIO TO PARTICIPATE IN THE CANACCORD GENUITY 45TH ANNUAL GROWTH CONFERENCE

MALVERN, PA., JULY 21, 2025 (GLOBE NEWSWIRE) -- TELA BIO, INC. ("TELA BIO") (NASDAQ: TELA), A COMMERCIAL-STAGE MEDICAL TECHNOLOGY COMPANY FOCUSED ON PROVIDING INNOVATIVE SOFT-TISSUE RECONSTRUCTION SOLUTIONS, TODAY ANNOUNCED THAT THE COMPANY WILL REPORT SECOND QUARTER 2025 FINANCIAL RESULTS ON MONDAY, AUGUST 11, 2025. TELA BIO'S MANAGEMENT WILL HOST A CONFERENCE CALL AND WEBCAST AT 4:30 P.M. ET THAT DAY TO DISCUSS THE FINANCIAL RESULTS AND PROVIDE A CORPORATE UPDATE.

TELA Bio, Inc.

TELA

Price

Financials Overview

Financial Reports

No items found.

Press Releases

TELA Bio, Inc.

TELA.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

TELA